Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director. His appointment is a critical step forward in advancing the Company’s recently acquired CGM technology and in driving its innovation and development to bring an advanced CGM solution to the global market.

“We are very excited to welcome Avinash to Trinity Biotech, where he will be instrumental in advancing our mission of introducing intelligent wearable biosensors, including CGMs, into markets all around the globe.  I believe that Avinash will bring a new level of knowledge and experience in the design and large-scale manufacture of advanced MedTech devices to this exciting project,” said John Gillard, Chief Executive Officer. “Our plan is to expand the usage of this critical technology across the hundreds of millions of people whose health is impacted by diabetes by introducing a high quality, more affordable and lower waste CGM.  Our CGM platform leverages our recent acquisition of European regulatory approved CGM technology and our lengthy experience in global diabetes management solutions, where we currently support approximately 10 million people with diabetes annually.  We are building a world class team of top talent to execute on our ambitious plans and investing in this business so as to maximize shareholder value creation.”

“I am thrilled to begin this new chapter and to embark on this pivotal and challenging role, joining the impressive Trinity team dedicated to making this state-of-art needle-free CGM solution accessible to patients worldwide. This transformational initiative promises a fast-paced, patient-centric, and innovative environment, with a strong sense of urgency to assist underserved patients affected by diabetes in improving their quality of life. I’m very excited to contribute to this meaningful and impactful endeavor,” said Avinash Kale.

Mr. Kale, a seasoned MedTech R&D, PMO & Innovation leader, with extensive global industry experience recently joined Trinity Biotech’s team in Ireland, from Philips Healthcare, The Netherlands. His career spans roles of increasing responsibility across Fortune 500+ firms Philips Healthcare Netherlands, Dell China, TATA India and Europe based scale-ups and start-ups. Mr. Kale has held key leadership positions, as Global Director of Engineering, Chief Technology Officer (CTO), Global Medical Device PMO, Head of Embedded Systems, R&D Program Management (PM), and Systems Engineering by steering global partners eco-system and teams across multiple sites and delivering cutting-edge solutions that drive meaningful innovations. Throughout his career, he has been a catalyst for impactful initiatives, including global product design & development, LEAN R&D, program leadership, business integration, emerging market initiatives, R&D Process innovation, product innovation, enabling technologies implementation, and transformation & change management, demonstrating his expertise in the end-to-end medical device solution life cycle.